argenx SE (ARGX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
€750.00
Buy
€760.00
€-3.60 (-0.48%)
Prices updated at 12 Dec 2025, 16:35 CET
| Prices minimum 15 mins delay
Prices in EUR
argenx SE, along with its subsidiaries is engaged in the bio-technical research on drugs and pharma processes for the treatment of oncological, autoimmune and inflammatory diseases.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 1,226m | 2,190m | |
| 1,108m | 1,963m | |
| -421m | -18m | |
| -34.30 | -0.81 | |
| -295m | 833m | |
| -192m | 105m | |
| Sales, General and administrative | 710m | 1,052m |
| Interest expenses | 904,000 | 2m |
| Provision for income taxes | -9m | -748m |
| Operating expenses | 1,529m | 1,981m |
| Income before taxes | -304m | 85m |
| Net income available to common shareholders | -295m | 833m |
| -5.16 | 13.92 | |
| Net interest income | 92m | 136m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -5.16 | 12.78 |
| Free cash flow per share | -12.1796 | -4.9361 |
| Book value/share | 43.6313 | 67.4129 |
| Debt equity ratio | 0.003747 | 0.005915 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 4,124m | 4,883m |
| Current liabilities | 423m | 670m |
| Total capital | 4,098m | 5,498m |
| Total debt | 20m | 39m |
| Total equity | 4,098m | 5,498m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 4,542m | 6,203m |
| Total liabilities | - | - |
| Cash and cash equivalents | 2,049m | 1,500m |
| Common stock | 59m | 61m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 801m | 2,049m |
| Cash dividends paid | - | - |
| -464m | -151m | |
| Investments (gains) losses | 308m | -718m |
| 2,049m | 1,500m | |
| Net income | - | - |
| -420m | -83m | |
| -44m | -68m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
